Georgina Speake

3.5k total citations · 1 hit paper
16 papers, 2.3k citations indexed

About

Georgina Speake is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Georgina Speake has authored 16 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 4 papers in Cancer Research. Recurrent topics in Georgina Speake's work include Lung Cancer Treatments and Mutations (13 papers), Colorectal Cancer Treatments and Studies (8 papers) and HER2/EGFR in Cancer Research (6 papers). Georgina Speake is often cited by papers focused on Lung Cancer Treatments and Mutations (13 papers), Colorectal Cancer Treatments and Studies (8 papers) and HER2/EGFR in Cancer Research (6 papers). Georgina Speake collaborates with scholars based in United Kingdom, United States and Netherlands. Georgina Speake's co-authors include Alison Armour, Emma Duffield, Yuri Rukazenkov, Haiyi Jiang, Tsu-Yi Chao, Tony Mok, Patrapim Sunpaweravong, Nagahiro Saijo, Sumitra Thongprasert and Swan-Swan Leong and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Georgina Speake

16 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

2011 1.2k citations Masahiro Fukuoka, Yi‐Long Wu et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Georgina Speake

Since Specialization

Citations

This map shows the geographic impact of Georgina Speake's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Georgina Speake with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Georgina Speake more than expected).

Fields of papers citing papers by Georgina Speake

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Georgina Speake. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Georgina Speake. The network helps show where Georgina Speake may publish in the future.

Co-authorship network of co-authors of Georgina Speake

This figure shows the co-authorship network connecting the top 25 collaborators of Georgina Speake. A scholar is included among the top collaborators of Georgina Speake based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Georgina Speake. Georgina Speake is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Integration of Laser Scanning and Three-dimensional Models in the Legal Process Following an Industrial Accident 2016 ·Safety and Health at Work ·Matthew Eyre, Patrick Foster, Georgina Speake, John Coggan	7
2	Abstract 912: Targeting HER family signaling in low HER2-expressing breast cancer: activity of the selective and equipotent EGFR, HER2 and HER3 signaling inhibitor, AZD8931, in models of low HER2-expressing disease. 2013 ·Cancer Research ·Gayle Marshall, Susan Ashton, Georgina Speake, Celina M. D’Cruz, Michael Grondine, Cath Trigwell, Graham Bigley, Garry Beran, (unknown), Teresa Klinowska	1
3	EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples 2012 ·Journal of Clinical Pathology ·Gillian Ellison, Guanshan Zhu, (unknown), Simon Dearden, Georgina Speake, Rose McCormack	235
4	Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS) breakdown → 2011 ·Journal of Clinical Oncology ·Masahiro Fukuoka, Yi‐Long Wu, Sumitra Thongprasert, Patrapim Sunpaweravong, Swan-Swan Leong, Virote Sriuranpong, Tsu-Yi Chao, Kazuhiko Nakagawa, (unknown), Nagahiro Saijo, Emma Duffield, Yuri Rukazenkov, Georgina Speake, Haiyi Jiang, Alison Armour, Ka‐Fai To, James Chih‐Hsin Yang, Tony Mok	1180
5	A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples 2010 ·Journal of Experimental & Clinical Cancer Research ·Gillian Ellison, Emma Donald, Gael McWalter, (unknown), Lynn M. Fletcher, James Sherwood, Mireille Cantarini, Maria Orr, Georgina Speake	132
6	AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer 2010 ·Clinical Cancer Research ·D. Mark Hickinson, Teresa Klinowska, Georgina Speake, John P. Vincent, Cath Trigwell, Judith Anderton, Sarah Beck, Gayle Marshall, Sara Davenport, Rowena Callis, Elizabeth Mills, Konstantina Grosios, Paul D. Smith, Bernard Barlaam, Robert W. Wilkinson, Donald Ogilvie	95
7	Identification of Biomarkers in Human Head and Neck Tumor Cell Lines That Predict For In Vitro Sensitivity to Gefitinib 2009 ·Clinical and Translational Science ·D. Mark Hickinson, Gayle Marshall, Garry Beran, Marileila Varella‐Garcia, Elizabeth Mills, (unknown), (unknown), (unknown), Gael McWalter, Rose McCormack, Paul A. Bunn, Tim French, (unknown), Brian R. Holloway, Fred R. Hirsch, Georgina Speake	17
8	Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different? 2009 ·Anti-Cancer Drugs ·Yuri Rukazenkov, Georgina Speake, Gayle Marshall, Judith Anderton, Barry R. Davies, Robert W. Wilkinson, D. Mark Hickinson, Alan Swaisland	43
9	Exploratory subset analysis according to prior endocrine treatment of two randomized phase II trials comparing gefitinib (G) with placebo (P) in combination with tamoxifen (T) or anastrozole (A) in hormone receptor-positive (HR+) metastatic breast cancer (MBC) 2009 ·Journal of Clinical Oncology ·Massimo Cristofanilli, Rachel Schiff, V. Valero, Renee Iacona, Ji Hee Yu, Georgina Speake, I. E. Smith, C. Kent Osborne	10
10	Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck 2009 ·Journal of Clinical Oncology ·J.S.W. Stewart, Ezra E.W. Cohen, Lisa Licitra, Carla M.L. van Herpen, Chonlakiet Khorprasert, Denis Soulières, P Vodvářka, Danny Rischin, Avgust M. Garin, Fred R. Hirsch, Marileila Varella‐Garcia, Serban Ghiorghiu, Laura Hargreaves, Alison Armour, Georgina Speake, Alan Swaisland, Everett E. Vokes	267
11	Epidermal growth factor receptor immunohistochemistry 2008 ·Cancer ·Fred R. Hirsch, Rafał Dziadziuszko, Nick Thatcher, Helen Mann, Claire Watkins, Dinah V. Parums, Georgina Speake, Brian R. Holloway, Paul A. Bunn, Wilbur A. Franklin	61
12	Gefitinib Versus Vinorelbine in Chemotherapy-Naïve Elderly Patients With Advanced Non–Small-Cell Lung Cancer (INVITE): A Randomized, Phase II Study 2008 ·Journal of Clinical Oncology ·Lucio Crinò, Federico Cappuzzo, Petr Zatloukal, Martin Reck, Miloš Pešek, Joyce Thompson, Hugo Ford, Fred R. Hirsch, Marileila Varella‐Garcia, Serban Ghiorghiu, Emma Duffield, Alison Armour, Georgina Speake, Michael Cullen	176
13	Role of EGFR but not HER2 or HER3 gene copy number in predicting sensitivity of head and neck squamous cell carcinoma (SCCHN) cell lines to EGFR tyrosine kinase inhibitors 2007 ·Journal of Clinical Oncology ·Marileila Varella‐Garcia, (unknown), Gayle Marshall, R. McCormack, Anderson J. Ryan, Fred R. Hirsch, Paul A. Bunn, D. Mark Hickinson, Georgina Speake	1
14	Epidermal growth factor receptor (EGFR) immunohistochemistry: Comparison of antibodies (Abs) and cut points to predict benefit from gefitinib in a phase III placebo-controlled study in advanced non-small cell lung cancer (NSCLC) 2007 ·Journal of Clinical Oncology ·Rafał Dziadziuszko, Fred R. Hirsch, Marileila Varella‐Garcia, N. Thatcher, Helen Mann, Claire Watkins, Georgina Speake, B. R. Holloway, P. A. Bunn, W. Franklin	4
15	A pharmacological comparison of gefitinib (IRESSA) and erlotinib 2006 ·Georgina Speake, Gayle Marshall, Judith Anderton, (unknown), Armelle Logié, (unknown), R. McCormack, P H Smith, B. R. Holloway, Barry R. Davies, D. Mark Hickinson	2
16	Recent developments related to the EGFR as a target for cancer chemotherapy 2005 ·Current Opinion in Pharmacology ·Georgina Speake, B. R. Holloway, Gerard Costello	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact